Related Experiment Videos
Epinephrine potentiates human platelet activation but is not an aggregating agent
1Institut National de la Santé et de la Recherche Médicale U311, Centre Régional de Transfusion Sanguine, Strasbourg, France.
The American Journal of Physiology
|December 1, 1988
Summary
Epinephrine does not directly cause platelet aggregation but potentiates other agonists by interacting with alpha 2-adrenergic receptors. This highlights its role in thrombotic disorders when catecholamine levels rise.
Area of Science:
- Hematology
- Pharmacology
- Biochemistry
Background:
- Epinephrine's role in thrombotic disorders is linked to increased catecholamine levels.
- Previous observations suggested epinephrine could induce platelet aggregation in vitro.
Purpose of the Study:
- To investigate the functional and biochemical responses of human platelets to epinephrine.
- To determine if epinephrine acts as a direct platelet aggregating agent.
Main Methods:
- Studied platelet aggregation, serotonin secretion, shape change, and ultrastructure in citrated plasma and washed platelets.
- Assessed effects on membrane fluidity, intracellular calcium (Ca2+), fibrinogen binding, and protein phosphorylation.
- Utilized alpha 2-adrenergic agonists and antagonists to probe receptor involvement.
Main Results:
- Epinephrine induced aggregation and serotonin secretion in citrated plasma, likely due to thrombin generation, not citrate.
- Washed platelets showed no direct response to epinephrine alone, including shape change, aggregation, or secretion.
- Epinephrine potentiated responses to other aggregating agents via alpha 2-adrenergic receptors, without direct effects on platelet function or structure.
Conclusions:
- Epinephrine is not a direct platelet aggregating agent.
- Epinephrine potentiates platelet activation by other agonists through alpha 2-adrenergic receptors.
- This potentiation mechanism is relevant to understanding thrombotic disorders associated with elevated catecholamines.